On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -2.89% | +3.07% | -76.67% |
09/05 | AEON Biopharma, Inc. Provides Update on Development Pipeline | CI |
03/05 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,09,700 KRW | -0.90% | -1.97% | 923M | ||
1.68 USD | -2.89% | +3.07% | 65.15M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.67% | 65.15M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.68% | 21.93B | |
-12.15% | 22.34B | |
-5.61% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd